RecruitingRecruiting
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
NCT07664735 · Outpace Bio, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
About this study
A phase 1a/b study to evaluate the safety and efficacy of OPB-201, an autologous PReferentially expressed Antigen of MElanoma (PRAME) T cell receptor (TCR) T cell therapy in recurrent endometrial and platinum-resistant ovarian cancer.
Eligibility criteria
Inclusion Criteria:
1. Age ≥ 18 years of age at the time of signing the informed consent form.
2. Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.
3. Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.
4. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
5. Measurable disease.
6. Consent to provide archived tumor tissue sample.
7. ECOG performance status of 0 or 1.
8. Adequate organ function.
9. HLA-A \*02:01 or HLA-A \*02:02
10. PRAME positive tumor
Exclusion Criteria:
1. Women of child-bearing potential who are pregnant or breastfeeding.
2. Uncontrolled bacterial, fungal, or viral infections.
3. Active infection requiring systemic therapy.
4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.
5. Any form of primary immunodeficiency.
6. Had an allogenic tissue/solid organ transplant.
7. Active autoimmune disease.
8. Concurrent treatment with systemic high dose corticosteroids.
9. Unresolved acute effects of any prior therapy.
10. Other exclusions as stated in the protocol.
Study design
Enrollment target: 30 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-06-30
Estimated completion: 2030-09
Last updated: 2026-11-19
Interventions
Biological: OPB-201
Primary outcomes
- • Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths. (2 years)
- • Incidence of dose-limiting-toxicities (DLTs) (28 days)
- • To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s) (2 years)
Sponsor
Outpace Bio, Inc. · industry
Contacts & investigators
ContactJohn Ferraro · contact · jferraro@outpacebio.vom · 3039290208
All locations (5)
UCSF - Helen Diller Family Comprehensive Cancer CenterRecruiting
San Francisco, California, United States
Emory - Winship Cancer InstituteRecruiting
Atlanta, Georgia, United States
Karmanos Cancer InstituteRecruiting
Detroit, Michigan, United States
University of MinnesotaRecruiting
Minneapolis, Minnesota, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States